Skip to content

Cardiovascular Status in Adrenal Insufficiency

Cardiovascular Status in Patients With Chronic Cortisol Deficiency (Adrenal Insufficiency)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03426319
Acronym
CVCORT-AI
Enrollment
68
Registered
2018-02-08
Start date
2013-08-31
Completion date
2014-06-30
Last updated
2018-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenal Insufficiency

Keywords

Primary adrenal insufficiency, Cardiovascular status, Metabolic profile

Brief summary

Within this trial, the cardiovascular status and metabolic profile of patients with chronic primary adrenal insufficiency is evaluated.

Detailed description

An unfavorable metabolic profile in patients with adrenal insufficiency (AI) under hormone replacement therapy with hydrocortisone (HC) has been revealed in one recent analysis. Furthermore an increased cardiovascular (CV) morbidity in AI is assumed. The aim of the study is to evaluate the metabolic profile and cardiovascular status in patients with primary AI. Patients with primary AI under standard replacement therapy with HC undergo detailed CV evaluation (including e.g. laboratory test, analysis of endothelial function, 24h blood pressure profile, Holter ECG, echocardiography and cardiac MRI).

Interventions

Cardiovascular evaluation includes anamnesis, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, echocardiography and cardiac MRI.

Sponsors

Wuerzburg University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Chronic primary adrenal insufficiency * Adequate hormone replacement therapy (\>3 years) * Age \>18 years * Patient's informed consent

Exclusion criteria

* Hormone replacement therapy with an other glucocorticoid than hydrocortisone * Pharmacotherapy with glucocorticoids * Congenital adrenal hyperplasia * Coronary heart disease * Heart failure * Systemic disease with (potential) cardiac involvement (e.g. amyloidosis, lung fibrosis) * Pregnancy * Chronic alcohol abuse * Malignant disease * Arterial hypertension * Chronic renal failure (MDRD \<60)

Design outcomes

Primary

MeasureTime frameDescription
Cardiovascular status - anamnesis12 monthsEvaluation of the cardiovascular status of patients with chronic adrenal insufficiency by anamnesis/documentation of cardiovascular risk factors. Prevalence of cardiovascular risk factors (diabetes, hypertension, hyperlipidemia, obesity) in participating patients.
Cardiovascular status - mean systolic blood pressure12 monthsMeasurement of the systolic resting blood pressure (in mmHg). Analysis of the mean systolic blood pressure (of all participating patients) and the number of patients with increased systolic blood pressure (\>140 mmHg).
Cardiovascular status - mean diastolic blood pressure12 monthsMeasurement of the diastolic resting blood pressure (in mmHg). Analysis of the mean diastolic blood pressure (of all participating patients).
Cardiovascular status - mean BMI12 monthsMeasurement of weight (in kg) and height (qm); weight and height will be combined to report the Body Mass Index/BMI (kg/qm). Analysis of the mean BMI (of all participating patients) and the number of patients with increased BMI (\>25 kg/qm).
Cardiovascular status - mean HbA1c12 monthsMeasurement of HbA1c-values (in %). Analysis of the mean HbA1c-value and the number of patients with increased HbA1c (\>6.5%).
Cardiovascular status - mean cholesterol-level12 monthsMeasurement of cholesterol-levels (in mg/dl). Analysis of the mean cholesterol-level and the number of patients with increased cholesterol-levels (\>200mg/dl).
Cardiovascular status - mean triglyceride-level12 monthsMeasurement of triglyceride-levels (in mg/dl). Analysis of the mean triglyceride-level and the number of patients with increased triglyceride-levels (\>200mg/dl).
Cardiovascular status - reactive hyperaemia index12 monthsEvaluation of the reactive hyperaemia index (endothelial function). Analysis of the number of patients with a pathological reactive hyperaemia index (pathological results ≤ 1.67).
Cardiovascular status - mean systolic blood pressure (24h blood pressure measurement)12 monthsMeasurement of the mean systolic blood pressure (in mmHg) by 24h blood pressure profiles. Analysis of the mean systolic blood pressure (of all participating patients) and the number of patients with an increased mean systolic blood pressure (\>140 mmHg).
Cardiovascular status - non-dipper-profiles12 monthsDocumentation of the number of patients with a non-dipper-profile during a 24h blood pressure measurement.
Cardiovascular status - mean ejection fraction12 monthsAnalysis of the mean ejection fraction (in %) (by echocardiography of all participating patients) and the number of patients with a pathologic ejection fraction (\<55%).
Cardiovascular status - diastolic function12 monthsMeasurement of the diastolic function by echocardiography. Analysis of the number of patients with a pathological diastolic function (E/A ratio; values \<1 were rated as pathological).
Cardiovascular status - pathological cardiac MRI12 monthsNumber of patients with pathological results (ejection fraction (\<55%), pericardial effusion, thrombus, adipose tissue, perfusion defects, late enhancement, valvular or wall motion abnormalities).

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026